Although the source of blood sCD137 in tumor patients needs to be further investigated, sCD137 is potentially derived from CD137+ Tregs in the tumor microenvironment, where most antitumor immune cells are in a suppressed state. This evidence concerns the gene TNFRSF9 and neoplasm.